Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
-0.005 (-1.18%)
May 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.40 - 0.42
52 week 0.40 - 1.30
Open 0.41
Vol. 12,219.00
Mkt cap 44.71M
P/E     -
Div/yield     -
EPS -0.02
Shares 106.44M
Beta 1.47
Inst. own     -

Key stats and ratios

Q4 (Nov '14) 2014
Net profit margin 10449.96% -2318.25%
Operating margin -10286.36% -2156.14%
EBITD margin - -1802.00%
Return on average assets 30.06% -40.18%
Return on average equity 35.81% -54.00%
CDP Score - -


100-545 Prom du Centropolis
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links


Acasti Pharma Inc. is a Canada-based biopharmaceutical company focused on the research, development and commercialization of new krill-oil based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, referred to as dyslipidemia. The Company owns a prescription drug candidate, CaPre, as well as a medical food, Onemia, which is available in the market. The Company is conducted a Phase II open label (COLT) study, the results of, which showed that CaPre was safe and effective in reducing triglycerides in patients with mild to severe hypertriglyceridemia. It is conducting a Phase II double blind (TRIFECTA) trial on CaPre to evaluate the safety and efficacy of CaPre on patients with hypertriglyceridemia. The Company is also conducting a Pharmacokinetics trial on CaPre in collaboration with Quintiles.

Officers and directors

Jerald J. Wenker Chairman of the Board
Andre Godin Interim President and Chief Executive Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Harlan W. Waksal M.D. Executive Vice President - Business and Scientific Affairs, Director
Age: 60
Tina Sampalis MD., Ph.D. Chief Global Strategy Officer
Ronald Denis Director
Henri Harland Director
Valier Boivin Independent Director
Jean-Claude Debard Independent Director
Reed V. Tuckson M.D. Independent Director